Should you run Cagrilintide or Tesofensine

Ever had two peptides on the table, both promising to shut off your appetite, and no clue which one actually earns a place in your fridge? Short answer: cagrilintide wins this one for almost everybody, and tesofensine is the pick only if you've got a genuinely specific reason to dodge a needle. Here's why I land there, and where I'd flip.

Two Different Switches, Not Two Flavors of the Same Drug

Before we get into who wins, you need to know these two peptides aren't even competing on the same turf. That trips people up CONSTANTLY.

Cagrilintide is an amylin analog. Amylin is a hormone your pancreas already makes every time you eat, and its whole job is telling your brainstem "okay, that's enough, put the fork down." Cagrilintide is that same signal, engineered to last about a week instead of a few minutes. Tesofensine isn't a peptide at all, and it isn't hormone mimicry either. It's a small-molecule pill that blocks your brain from reabsorbing serotonin, noradrenaline, and dopamine, so all three linger longer and your whole seek-it, want-it, feel-satisfied circuitry gets turned up at once.

Think of it like two smoke detectors wired into the same house. One sits in the kitchen and decides how much you even want to be cooking in there in the first place. The other sits down the hall and decides when you've had enough and it's time to walk away. Cagrilintide is the hallway detector. Tesofensine is wired into BOTH detectors and the thermostat and the stereo all at once, because it's hitting three neurotransmitters system-wide instead of one gut-to-brain signal.

That difference in DESIGN is exactly why one of these has a much bigger, cleaner human evidence pile than the other.

The Evidence Isn't Close, and I Wish It Were

I've read a stack of trial data on both of these, and I'll be honest: I wanted tesofensine to have a stronger case, because an oral option (no vials, no reconstitution, no ice pack) would be a genuinely great fit for a lot of my readers.

It doesn't hold up. Tesofensine's headline number comes from a single Phase 2 trial back in 2008: 203 people, 24 weeks, topping out around 10.6% placebo-subtracted weight loss at the 1.0 mg dose. That trial is old enough to have a driver's license now, and nothing bigger ever followed it. Tesofensine never made it to Phase 3 in obesity.

Cagrilintide, meanwhile, got dragged through the wringer that actually matters: a 706-person Phase 2 monotherapy trial putting the top dose at 10.8% weight loss on its own, then a Phase 2 bridge trial in type 2 diabetes that justified funding a real Phase 3 program, and THEN a 3,417-person Phase 3 trial (CagriSema, cagrilintide stacked with semaglutide) landing at 20.4% weight loss over 68 weeks. A pooled meta-analysis confirms the combo beats semaglutide alone on the scale, with the honest tradeoff that GI side effects run higher too. That's not "promising early data." That's a molecule that walked the entire clinical gauntlet.

Yup. It's true. Cagrilintide alone, no semaglutide riding shotgun, still beat the tesofensine ceiling at a comparable dose.

The Rob-Peter-To-Pay-Paul Problem With Tesofensine

This is the part that should worry you more than any weight-loss percentage. Tesofensine's whole mechanism is your body borrowing from one system to prop up another, classic rob Peter to pay Paul, and eventually somebody notices the withdrawal.

Here's the actual mechanics: cranking up dopamine and noradrenaline system-wide is what suppresses your appetite, and that same cranking nudges your heart rate up (as much as 8 beats per minute) and your blood pressure up a few points, dose-dependent. You can't get one without some of the other. It's baked into HOW the drug works, not a rare footnote in small print.

Saniona, the company that owns tesofensine now, knows it. Their newer combination product literally adds a beta-blocker just to blunt the heart-rate bump their own drug causes. That's a hell of an admission to build right into your own pharmacology.

Cagrilintide's downside list looks different: nausea and some GI noise during titration, plus the real risk (same as any GLP-1-family peptide) that your appetite goes quiet FAST and you accidentally undereat protein. Annoying, manageable, nothing close to a cardiovascular tradeoff baked into the mechanism itself.

The Supply Chain Might Be the Real Deciding Vote

Even if you called the evidence and the mechanism a wash, there's a third factor that breaks the tie hard: what you can actually GET, and whether you can trust what's in it.

Cagrilintide is sold research-use-only through vendors running independent lab testing. US Pure Peptides, OHM's primary route for it, publishes ISO 17025-accredited third-party COAs so you know the vial actually contains cagrilintide at the purity it claims (code OHM20 there for 20% off). Heads up: OHM has an affiliate relationship with the vendors linked here, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence supports.

Tesofensine has no clean version of that story. Not FDA-approved anywhere in the US, not eligible for compounding, not sitting in any verified-vendor catalog with a COA next to it. The only sellers are unverified "research chemical" sites, the exact tier independent testing keeps catching underdosed or contaminated. Nope, not with a cardiovascular-liability drug. For something whose whole risk profile is heart rate and blood pressure, that's the wrong place to be rolling dice on what's actually in the capsule.

So, Which One Do You Actually Run?

For almost every reader asking this question: cagrilintide. Stronger mechanism story, a real Phase 3 program behind it, a side-effect profile that's manageable instead of mechanistically baked-in, and a supply chain you can actually verify. If you're already on a fat-loss stack with retatrutide or semaglutide and still fighting food noise, cagrilintide is your gap-filler. If you're not on a GLP-1 at all and just want the amylin pathway solo, it holds up fine standalone too, per that 706-person trial.

Tesofensine earns a place in exactly one conversation: you've got a documented reason to avoid injectables altogether, your blood pressure and resting heart rate are genuinely normal and you're actually tracking them, and you understand you're accepting Phase-2-only evidence with no clean US sourcing path behind it. That's a narrow lane. Most people asking "cagrilintide vs tesofensine" aren't standing in it.

Now the part my lawyer makes me say, and honestly he's right: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

On the actual numbers: cagrilintide's studied dose range runs 0.3 to 4.5 mg weekly, and the real-world titration most people run climbs from 0.25 mg weekly for the first month up to a 2.4 mg weekly maintenance dose, the same number CagriSema used in its Phase 3 trial. Tesofensine's studied range in the Astrup trial was 0.25 to 1.0 mg daily, with 0.5 mg as the spot the researchers themselves flagged as the best trade between effect and side effects.

Learn which switch you're actually flipping before you pick a peptide. That's the whole game.

Thanks for reading. In health, Rick Gold.